Lauren Welch, Kammi Fox-Kay, and Cathy Simmons discuss their approaches to educating patients on the importance of waiting for biomarker testing before starting therapy for non–small cell lung cancer (NSCLC) to individualize therapy with the treatment that is best suited for their cancer and to achieve the best outcomes.
